Bright Minds Biosciences (NASDAQ:DRUG) Sees Strong Trading Volume – Here’s What Happened

Bright Minds Biosciences Inc. (NASDAQ:DRUG) shares saw strong trading volume on Wednesday . 355,033 shares traded hands during trading, an increase of 87% from the previous session’s volume of 189,967 shares.The stock last traded at $77.08 and had previously closed at $76.78.

Key Bright Minds Biosciences News

Here are the key news stories impacting Bright Minds Biosciences this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating on Bright Minds Biosciences and reiterated a $145 price target, implying significant upside versus the current share price. Benzinga
• Positive Sentiment: The analyst slightly raised some near- and medium-term EPS estimates, including Q1 2027, Q3 2027, Q4 2027 and FY2026, which may have helped sentiment around the stock. Street Insider
• Neutral Sentiment: The updated forecasts still call for substantial losses over the next several years, so the revisions are supportive but not a sign of near-term profitability.
• Negative Sentiment: Some estimates were cut, including Q2 2027, Q3 2026, Q4 2026, FY2027, FY2028, and FY2029, which tempers the bullish analyst tone.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on DRUG. Piper Sandler reiterated an “overweight” rating and set a $220.00 price objective (up from $190.00) on shares of Bright Minds Biosciences in a research note on Wednesday, May 20th. BTIG Research reiterated a “buy” rating and set a $147.00 price objective on shares of Bright Minds Biosciences in a research note on Monday, March 30th. HC Wainwright reiterated a “buy” rating and set a $145.00 price objective on shares of Bright Minds Biosciences in a research note on Monday. Robert W. Baird set a $126.00 price objective on shares of Bright Minds Biosciences in a research note on Friday, February 13th. Finally, Jefferies Financial Group assumed coverage on shares of Bright Minds Biosciences in a research note on Monday, April 13th. They set a “buy” rating and a $145.00 price objective on the stock. Six equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $143.83.

Bright Minds Biosciences Price Performance

The company has a 50-day simple moving average of $82.27 and a two-hundred day simple moving average of $79.96. The stock has a market capitalization of $757.05 million, a price-to-earnings ratio of -31.88 and a beta of -5.53.

Bright Minds Biosciences (NASDAQ:DRUG) last announced its quarterly earnings results on Wednesday, May 20th. The company reported ($0.80) EPS for the quarter, beating the consensus estimate of ($0.86) by $0.06. Research analysts anticipate that Bright Minds Biosciences Inc. will post -4.99 EPS for the current year.

Insider Activity at Bright Minds Biosciences

In other Bright Minds Biosciences news, major shareholder Cormorant Asset Management, Lp sold 109,331 shares of the firm’s stock in a transaction that occurred on Tuesday, April 28th. The shares were sold at an average price of $89.50, for a total value of $9,785,124.50. Following the sale, the insider owned 950,000 shares in the company, valued at approximately $85,025,000. This trade represents a 10.32% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 42.66% of the company’s stock.

Institutional Investors Weigh In On Bright Minds Biosciences

Several large investors have recently made changes to their positions in the company. Vivo Capital LLC increased its holdings in shares of Bright Minds Biosciences by 11.1% during the first quarter. Vivo Capital LLC now owns 557,172 shares of the company’s stock valued at $40,657,000 after purchasing an additional 55,555 shares during the period. Bank of America Corp DE increased its holdings in shares of Bright Minds Biosciences by 28.8% during the first quarter. Bank of America Corp DE now owns 19,422 shares of the company’s stock valued at $1,417,000 after purchasing an additional 4,347 shares during the period. Janus Henderson Group PLC increased its holdings in shares of Bright Minds Biosciences by 11.1% during the first quarter. Janus Henderson Group PLC now owns 1,284,324 shares of the company’s stock valued at $93,518,000 after purchasing an additional 128,329 shares during the period. ADAR1 Capital Management LLC increased its holdings in shares of Bright Minds Biosciences by 868.6% during the first quarter. ADAR1 Capital Management LLC now owns 33,900 shares of the company’s stock valued at $2,474,000 after purchasing an additional 30,400 shares during the period. Finally, Orbimed Advisors LLC acquired a new position in shares of Bright Minds Biosciences during the first quarter valued at $2,919,000. Institutional investors and hedge funds own 40.52% of the company’s stock.

About Bright Minds Biosciences

Bright Minds Biosciences Inc, trading on the NASDAQ under the symbol DRUG, is a clinical-stage biotechnology company focused on developing novel small-molecule therapeutics for mental health and neurodegenerative disorders. The company’s research leverages proprietary chemistry platforms to create serotonin-modulating and neuroprotective compounds derived from psychedelic-inspired structures. Bright Minds aims to address unmet needs in conditions such as major depressive disorder, post-traumatic stress disorder and Alzheimer’s disease through orally administered treatments.

The company’s lead candidate, BMB-101, is an oral 5-HT2A receptor-modulating compound in clinical development for mood and anxiety disorders.